Immunovant Inc. (IMVT)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
IMVT shares climb as IMVT-1402 posts encouraging data, advances across autoimmune diseases and benefits from a cash runway extending through launch.
Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential
Immunovant's underlying bull case has now moved away from batoclimab and toward IMVT-1402. This newer asset has encouraging data for difficult-to-treat RA. By week 16, 72.7% of hard-to-treat RA patients had good responses with IMVT-1402. IMVT also has a solid balance sheet this time around. And management believes its runway is sufficient through their next readouts.
Immunovant Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 86 | $1,667.98 | $3,441.72 | $1,773.74 | 106.34% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 10 | $248.4 | $401.7 | $153.3 | 61.71% |
 Farallon Capital Farallon Capital Management LLC | 1.55M | $38.42M | $62.28M | $23.86M | 62.1% |
| BG Bart Gancher Intech Investment Management LLC | 29,979 | $640,263.3 | $1.2M | $563,993.13 | 88.09% |
 John H. Burbank III Passport Capital LLC | 5.46M | $115.09M | $219.24M | $104.15M | 90.5% |
Immunovant Inc. (IMVT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Immunovant Inc. ever had a stock split?
Immunovant Inc. Profile
| Biotechnology Industry | Healthcare Sector | Eric Venker CEO | NASDAQ (NGS) Exchange | 45258J102 CUSIP |
| US Country | 315 Employees | - Last Dividend | - Last Split | 21 Jun 2019 IPO Date |
Overview
Immunovant, Inc. is a forward-looking biopharmaceutical company engaged in the development of innovative treatments for autoimmune diseases. Positioned at the clinical stage, Immunovant focuses on pioneering monoclonal antibody therapies, a cutting-edge segment of medicinal treatment that harnesses the body's immune system to combat disease. Headquartered in New York, New York, Immunovant operates under the umbrella of its parent company, Roivant Sciences Ltd., indicating a strong backing and extensive resources for its research endeavors and potential market influence.
Products and Services
- Batoclimab
- Myasthenia Gravis: A chronic autoimmune neuromuscular disease that leads to varying degrees of skeletal muscle weakness.
- Thyroid Eye Disease: An autoimmune condition that affects the orbit around the eye, characterized by inflammation, swelling, and eventually fibrosis, leading to discomfort and vision problems.
- Chronic Inflammatory Demyelinating Polyneuropathy: A neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms.
- Graves Diseases: An autoimmune disorder that results in the overproduction of thyroid hormones (hyperthyroidism).
- Warm Autoimmune Hemolytic Anemia: A condition where the immune system destroys red blood cells, leading to anemia.
A standout in Immunovant's portfolio, batoclimab represents a significant advancement in the monoclonal antibody domain, primarily targeting the neonatal fragment crystallizable receptor (FcRn). This novel, fully human antibody is currently under development for multiple autoimmune conditions, demonstrating the company’s commitment to addressing a range of challenging diseases. The conditions targeted by batoclimab include:
